{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T15:46:39Z","timestamp":1776872799321,"version":"3.51.2"},"reference-count":40,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"DIO Medical"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Patients with diabetes mellitus (DM) undergoing percutaneous coronary intervention face higher risks of restenosis and adverse cardiovascular outcomes compared to those without DM. This study compared the real-world safety and effectiveness of the Cre8\/Cre8 EVO stents in patients with and without diabetes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed an investigator-initiated, prospective, single-arm observational trial at 28 sites in South Korea. The primary endpoint was a composite of cardiac death, target vessel-related myocardial infarction (MI), and any clinically driven repeat revascularization at 12 months. All-cause mortality was a key secondary endpoint. The adjusted outcomes of DM and non-DM groups were compared using 1:1 propensity score (PS) matching.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 2,043 patients (66.0\u2009\u00b1\u200911.5 years of age; 76.2% male) were analyzed. Diabetic patients (n\u2009=\u2009773; HbA1c 7.3\u2009\u00b1\u20091.4%) were more likely to be older, female, and have hypertension, dyslipidemia, or chronic kidney disease. Among these, 20.2% (156 patients) were using insulin. There were 54 cases of primary endpoint, 22 (cumulative incidence, 3.4%) in the DM group and 32 (3.0%) in the non-DM group (p\u2009=\u20090.61). The DM group exhibited a higher all-cause mortality rate compared to the non-DM group (2.1% vs. 1.3%; p\u2009=\u20090.19). The adjusted risk of 1-year primary endpoint was similar between the DM and non-DM groups (hazard ratio, 1.20; 95% confidence interval, 0.63\u20132.30), with comparable safety profiles.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this real-world study, the DM group treated with amphilimus-eluting stents demonstrated sufficient safety and effectiveness at 12 months, with a similar occurrence of cardiovascular events compared to the non-DM group.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0336017","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T18:24:21Z","timestamp":1762799061000},"page":"e0336017","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of polymer-free amphilimus-eluting stent in patients with and without diabetes mellitus: A prospective, multicenter observational study"],"prefix":"10.1371","volume":"20","author":[{"given":"Subin","family":"Lim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ju Hyeon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4832-6678","authenticated-orcid":true,"given":"Soon Jun","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung-Joon","family":"Cha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyung Joon","family":"Joo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae Hyoung","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheol Woong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Do-Sun","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae-Youn","family":"Moon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soon Yong","family":"Suh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin Man","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,11,10]]},"reference":[{"issue":"8","key":"pone.0336017.ref001","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1161\/CIRCULATIONAHA.111.031070","article-title":"Differential clinical responses to everolimus-eluting and Paclitaxel-eluting coronary stents in patients with and without diabetes mellitus","volume":"124","author":"GW Stone","year":"2011","journal-title":"Circulation"},{"issue":"25","key":"pone.0336017.ref002","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1016\/j.jacc.2010.10.006","article-title":"Outcomes in diabetic and nondiabetic patients treated with everolimus- or paclitaxel-eluting stents: results from the SPIRIT IV clinical trial (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System)","volume":"56","author":"DJ Kereiakes","year":"2010","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"pone.0336017.ref003","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1161\/01.CIR.0000109693.64957.20","article-title":"Outcomes in patients with diabetes mellitus undergoing percutaneous coronary intervention in the current era: a report from the Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial","volume":"109","author":"V Mathew","year":"2004","journal-title":"Circulation"},{"issue":"5","key":"pone.0336017.ref004","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jcin.2013.12.201","article-title":"Everolimus-eluting Xience v\/Promus versus zotarolimus-eluting resolute stents in patients with diabetes mellitus","volume":"7","author":"KW Park","year":"2014","journal-title":"JACC Cardiovasc Interv"},{"issue":"2","key":"pone.0336017.ref005","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.114.001441","article-title":"Comparison of a novel biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: results of the randomized BIOFLOW-II trial","volume":"8","author":"S Windecker","year":"2015","journal-title":"Circ Cardiovasc Interv"},{"issue":"6","key":"pone.0336017.ref006","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.jacc.2018.11.001","article-title":"Long-Term Survival Following Multivessel Revascularization in Patients With Diabetes: The FREEDOM Follow-On Study","volume":"73","author":"ME Farkouh","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"pone.0336017.ref007","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1161\/01.CIR.0000140721.27004.4B","article-title":"Beyond restenosis: five-year clinical outcomes from second-generation coronary stent trials","volume":"110","author":"DE Cutlip","year":"2004","journal-title":"Circulation"},{"issue":"25","key":"pone.0336017.ref008","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1056\/NEJMoa1211585","article-title":"Strategies for multivessel revascularization in patients with diabetes","volume":"367","author":"ME Farkouh","year":"2012","journal-title":"N Engl J Med"},{"issue":"2","key":"pone.0336017.ref009","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.115.003255","article-title":"Impact of Diabetic Status on Outcomes After Revascularization With Drug-Eluting Stents in Relation to Coronary Artery Disease Complexity: Patient-Level Pooled Analysis of 6081 Patients","volume":"9","author":"KC Koskinas","year":"2016","journal-title":"Circ Cardiovasc Interv"},{"issue":"1","key":"pone.0336017.ref010","first-page":"81","article-title":"Biodegradable polymer drug-eluting stent vs. contemporary durable polymer drug-eluting stents in patients with diabetes: a meta-analysis of randomized controlled trials","volume":"6","author":"C Bavishi","year":"2020","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"issue":"2","key":"pone.0336017.ref011","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jacasi.2021.07.009","article-title":"Effectiveness and Safety of Contemporary Drug-Eluting Stents in Patients With Diabetes Mellitus","volume":"1","author":"Y Yang","year":"2021","journal-title":"JACC Asia"},{"issue":"4","key":"pone.0336017.ref012","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1080\/17434440.2020.1740587","article-title":"The Cre8 amphilimus-eluting stent for the treatment of coronary artery disease: safety and efficacy profile","volume":"17","author":"CA Pivato","year":"2020","journal-title":"Expert Rev Med Devices"},{"issue":"1","key":"pone.0336017.ref013","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jcin.2015.09.020","article-title":"A Randomized Comparison of Reservoir-Based Polymer-Free Amphilimus-Eluting Stents Versus Everolimus-Eluting Stents With Durable Polymer in Patients With Diabetes Mellitus: The RESERVOIR Clinical Trial","volume":"9","author":"R Romaguera","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"key":"pone.0336017.ref014","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ijcard.2017.06.028","article-title":"Polymer-free amphilimus-eluting stent versus biodegradable polymer biolimus-eluting stent in patients with and without diabetes mellitus","volume":"245","author":"C Godino","year":"2017","journal-title":"Int J Cardiol"},{"issue":"5","key":"pone.0336017.ref015","first-page":"884","article-title":"Clinical outcomes with reservoir-based polymer-free amphilimus-eluting stents in real-world patients according to diabetes mellitus and complexity: The INVESTIG8 registry","volume":"91","author":"G Sardella","year":"2018","journal-title":"Catheter Cardiovasc Interv"},{"key":"pone.0336017.ref016","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ijcard.2019.10.058","article-title":"Five-year clinical outcome of multicenter randomized trial comparing amphilimus - with paclitaxel-eluting stents in de novo native coronary artery lesions","volume":"301","author":"D Carri\u00e9","year":"2020","journal-title":"Int J Cardiol"},{"issue":"2","key":"pone.0336017.ref017","first-page":"366","article-title":"Clinical outcomes after permanent polymer or polymer-free stent implantation in patients with diabetes mellitus: The ReCre8 diabetes substudy","volume":"99","author":"ND van Hemert","year":"2022","journal-title":"Catheter Cardiovasc Interv"},{"issue":"6","key":"pone.0336017.ref018","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.115.002943","article-title":"Stent Polymers: Do They Make a Difference","volume":"9","author":"KD Rizas","year":"2016","journal-title":"Circ Cardiovasc Interv"},{"issue":"15","key":"pone.0336017.ref019","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/j.jacc.2011.10.903","article-title":"Role of endothelial shear stress in stent restenosis and thrombosis: pathophysiologic mechanisms and implications for clinical translation","volume":"59","author":"KC Koskinas","year":"2012","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"pone.0336017.ref020","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/eurheartj\/ehab790","article-title":"Amphilimus- vs. zotarolimus-eluting stents in patients with diabetes mellitus and coronary artery disease: the SUGAR trial","volume":"43","author":"R Romaguera","year":"2022","journal-title":"Eur Heart J"},{"issue":"2","key":"pone.0336017.ref021","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/eurheartj\/ehy394","article-title":"2018 ESC\/EACTS Guidelines on myocardial revascularization","volume":"40","author":"F-J Neumann","year":"2019","journal-title":"Eur Heart J"},{"issue":"3","key":"pone.0336017.ref022","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","article-title":"2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes","volume":"41","author":"J Knuuti","year":"2020","journal-title":"Eur Heart J"},{"issue":"14","key":"pone.0336017.ref023","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","article-title":"2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","volume":"42","author":"J-P Collet","year":"2021","journal-title":"Eur Heart J"},{"issue":"3","key":"pone.0336017.ref024","article-title":"2021 ACC\/AHA\/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"JS Lawton","year":"2022","journal-title":"Circulation"},{"issue":"2","key":"pone.0336017.ref025","first-page":"101259","article-title":"SCAI Expert Consensus Statement on the Management of Calcified Coronary Lesions","volume":"3","author":"RF Riley","year":"2024","journal-title":"J Soc Cardiovasc Angiogr Interv"},{"issue":"18","key":"pone.0336017.ref026","first-page":"1845","article-title":"Ischemic outcomes after coronary intervention of calcified vessels in acute coronary syndromes. Pooled analysis from the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) and ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) TRIALS","volume":"63","author":"P G\u00e9n\u00e9reux","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"pone.0336017.ref027","first-page":"743","article-title":"Impact of Diabetes on Long-Term Outcomes of Percutaneous Coronary Intervention for Coronary Bifurcation Lesions","volume":"106","author":"S Lim","year":"2025","journal-title":"Catheter Cardiovasc Interv"},{"issue":"7","key":"pone.0336017.ref028","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1021\/acs.bioconjchem.5b00192","article-title":"Polymer-Free Drug-Eluting Stents: An Overview of Coating Strategies and Comparison with Polymer-Coated Drug-Eluting Stents","volume":"26","author":"W Chen","year":"2015","journal-title":"Bioconjug Chem"},{"issue":"1","key":"pone.0336017.ref029","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s12933-020-01145-x","article-title":"Clinical outcome of biodegradable polymer sirolimus-eluting stent and durable polymer everolimus-eluting stent in patients with diabetes","volume":"19","author":"R Kakizaki","year":"2020","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"pone.0336017.ref030","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1161\/CIRCINTERVENTIONS.109.877522","article-title":"Polymer-free biolimus a9-coated stent demonstrates more sustained intimal inhibition, improved healing, and reduced inflammation compared with a polymer-coated sirolimus-eluting cypher stent in a porcine model","volume":"3","author":"N Tada","year":"2010","journal-title":"Circ Cardiovasc Interv"},{"issue":"1","key":"pone.0336017.ref031","first-page":"56","article-title":"Relative resistance to Mammalian target of rapamycin inhibition in vascular smooth muscle cells of diabetic donors","volume":"13","author":"Jr Lightell DJ","year":"2013","journal-title":"Ochsner J"},{"issue":"17","key":"pone.0336017.ref032","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1161\/01.CIR.0000095272.67948.17","article-title":"Association of insulin resistance, hyperleptinemia, and impaired nitric oxide release with in-stent restenosis in patients undergoing coronary stenting","volume":"108","author":"P Piatti","year":"2003","journal-title":"Circulation"},{"issue":"1","key":"pone.0336017.ref033","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1161\/01.ATV.0000110908.43721.ad","article-title":"From fat fighter to risk factor: the zigzag trek of leptin","volume":"24","author":"N Werner","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"48","key":"pone.0336017.ref034","doi-asserted-by":"crossref","first-page":"19006","DOI":"10.1073\/pnas.0809743105","article-title":"Leptin-enhanced neointimal hyperplasia is reduced by mTOR and PI3K inhibitors","volume":"105","author":"J Shan","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"pone.0336017.ref035","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.jacc.2005.09.030","article-title":"Increased myocardial fatty acid metabolism in patients with type 1 diabetes mellitus","volume":"47","author":"P Herrero","year":"2006","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"pone.0336017.ref036","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1152\/physrev.00003.2009","article-title":"Membrane fatty acid transporters as regulators of lipid metabolism: implications for metabolic disease","volume":"90","author":"JFC Glatz","year":"2010","journal-title":"Physiol Rev"},{"issue":"2","key":"pone.0336017.ref037","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jcin.2011.10.013","article-title":"Clinical presentation, management, and outcomes of angiographically documented early, late, and very late stent thrombosis","volume":"5","author":"EJ Armstrong","year":"2012","journal-title":"JACC Cardiovasc Interv"},{"issue":"16","key":"pone.0336017.ref038","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1161\/CIRCULATIONAHA.110.981688","article-title":"Frequency and predictors of stent thrombosis after percutaneous coronary intervention in acute myocardial infarction","volume":"123","author":"GD Dangas","year":"2011","journal-title":"Circulation"},{"issue":"5","key":"pone.0336017.ref039","doi-asserted-by":"crossref","first-page":"683","DOI":"10.3904\/kjim.2023.129","article-title":"Clinical safety and effectiveness of the Genoss drug-eluting stent in real-world clinical practice","volume":"38","author":"YJ Youn","year":"2023","journal-title":"Korean J Intern Med"},{"issue":"5","key":"pone.0336017.ref040","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1001\/jamacardio.2024.0059","article-title":"Quantitative coronary angiography vs intravascular ultrasonography to guide drug-eluting stent implantation: a randomized clinical trial","volume":"9","author":"PH Lee","year":"2024","journal-title":"JAMA Cardiol"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0336017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T18:24:27Z","timestamp":1762799067000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0336017"}},"subtitle":[],"editor":[{"given":"Prakash","family":"Sojitra","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,11,10]]},"references-count":40,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11,10]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0336017","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,10]]}}}